×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Indivior Completes Acquisition of Opiant Pharmaceuticals, Inc.
PR Newswire
PRNewswire/ -- Indivior PLC (LSE: INDV) ("Indivior" or the "Company") today announced that it has completed the acquisition of Opiant...
14 months ago
Latham Watkins Advises Opiant Pharmaceuticals Sale Indivior PLC
Latham & Watkins LLP
Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) has announced that it has entered into a definitive merger agreement to be acquired by Indivior...
18 months ago
Indivior agrees to acquire Opiant Pharmaceuticals for $145m
Pharmaceutical Technology
Indivior has signed a definitive agreement for the acquisition of all outstanding shares of Opiant Pharmaceuticals for nearly $145m.
18 months ago
Narcan Owner Opiant to Be Acquired by Indivior for $145 Million
WSJ
The combination of addiction-drug makers could tap into billions of dollars in settlement and federal funds aimed at expanding access to...
18 months ago
Opiant Pharmaceuticals, Inc.'s (NASDAQ:OPNT) largest shareholders are individual investors with 52% ownership ...
Yahoo Finance
Opiant Pharmaceuticals, Inc.'s (NASDAQ:OPNT) largest shareholders are individual investors with 52% ownership, institutions own 33%.
15 months ago
Indivior To Acquire Opiant Pharmaceuticals USA - English - USA - English
PR Newswire
PRNewswire/ -- Indivior PLC (LON: INDV) ("Indivior" or the "Company") and Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) ("Opiant") today...
18 months ago
Opiant Pharmaceuticals Announces Third Quarter 2022 Financial Results
GlobeNewswire
SANTA MONICA, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical...
18 months ago
Opiant Pharmaceuticals: Nano-Cap Buyout With Interesting CVR Thrown In (NASDAQ:OPNT)
Seeking Alpha
The CVR helps to bridge the gap during an acquisition, and the Opiant Pharmaceuticals CVR looks attractive. Click to see this OPNT special...
16 months ago
$145 million pharma acquisition to help launch opioid overdose drug
European Pharmaceutical Review
Indivior's $145 million acquisition of Opiant Pharmaceuticals will support the launch of OPNT003, an opioid overdose reversal agent.
18 months ago
Opiant (OPNT) Stock Skyrockets on Indivior's $145M Buyout Offer - TipRanks.com
Tipranks
UK-based Indivior PLC (OTCMKTS:INVVY) (GB:INDV) has offered to buy U.S.-based Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) for roughly $145 million.
18 months ago